Project Title:
Target ONECUT2: A Master Regulator of Lethal Prostate Cancer
Project Overview:
Prostate cancer progression into lethal treatment-resistant prostate cancer remains a major clinical problem associated with poor outcomes. In a recently published, first-in-field study, Dr. Freeman discovered a developmental transcription factor called ONECUT-2 (OC2), a master regulator of androgen receptor networks in prostate cancer, in addition to a molecular inhibitor of OC2. This inhibitor exhibits tremendously potent anticancer activity in models. Dr. Freeman will be developing a potential novel therapy option which may prevent lethal prostate cancer progression, as well as lung, pancreatic, and other OC2-driven cancers.
Principle Investigators:
Baylor College of Medicine
Salma Kaochar, PhD
Additional Investigators:
Cedars-Sinai Medical Center
Ramachandran Murali
Stephen Freedland, MD
Chen Qian, PhD
Catherine Grasso, PhD
University of Utah
Beatrice Knudsen, MD, PhD
Dana Farber Cancer Institute
Leigh Ellis, PhD
Baylor College of Medicine
Nicholas Mitsiades, MD, PhD
Cristian Coarfa, PhD
Amit Dash, PhD